Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Oncotype DX Breast Recurrence Score® test

Putting your tumor to the chemotherapy test

You’ve been diagnosed with stage I-IIIA hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. Now, you have treatment choices to make. Do you really need chemotherapy, or is your cancer likely to respond to hormone therapy alone? Your doctor has ordered the Breast Recurrence Score® test to help you find out.

See how this genomic test has helped over a million patients with early-stage invasive breast cancer choose the most appropriate treatment option for them.

Personalized insights for personalized treatment

Just as every patient is different, so is every tumor. The Breast Recurrence Score test uses genomics to give you and your doctor important risk information about how your individual tumor will likely behave. Valuable insights include:

  • How likely you are to benefit from chemotherapy
  • How likely your tumor is to spread
  • The risk of your cancer recurring
  • How likely your tumor is to respond to hormone therapy alone

Reasons to get tested:

The Breast Recurrence Score test is the only test proven to predict chemotherapy benefit

Studies have consistently shown that the Breast Recurrence Score test is the only test that can predict whether or not you’ll benefit from chemotherapy.

More than 1.5 million breast, prostate, and colon cancer patients have relied on an Oncotype DX® test for insights that help guide their treatment decisions

Without these tests, your doctors can only estimate how likely your cancer is to return by looking at factors such as age, tumor size, tumor grade, and lymph node status.

The Breast Recurrence Score test is included in every major breast cancer treatment guideline

Including the National Comprehensive Cancer Network® (NCCN®), American Society of Clinical Oncology (ASCO), the St. Gallen International Consensus Panel, the National Institute for Health and Care Excellence (NICE), and the European Society for Medical Oncology (ESMO)

Is the Breast Recurrence Score test right for you?

You may be a candidate for the Breast Recurrence Score test if:

  • You’ve been recently diagnosed with invasive breast cancer
  • Your cancer is stage I, II, or IIIA
  • Your breast cancer is hormone receptor-positive (HR+) and HER2-negative (HER2-)

NOTE: If you’ve been diagnosed with non-invasive breast cancer, ductal carcinoma in situ (confined to milk ducts, also known as DCIS), you may be eligible for the Oncotype DX Breast DCIS Score® test.

86%
of Breast Recurrence Score test patients have $0 financial responsibility*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how Breast Recurrence Score test will be covered.

91%
of Breast Recurrence Score test patients have a financial responsibility of <$100*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all the cost of the Breast Recurrence Score test if they have not satisfied their deductible.

*The numbers cited are based on historical patient billing data from 1/2/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages you to contact your insurer with questions about Oncotype DX Breast Recurrence Score test coverage.